MLTXMoonLake Immunotherapeutics
Price
-80%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 9% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for MLTX today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Watch
We are a clinical stage biotechnology company advancing therapies to address significant unmet needs in inflammatory skin and joint diseases. We are currently a single asset company focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody, that we exclusively licensed from MHKDG and that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 30, 2026On September 30, 2026, MoonLake Immunotherapeutics (the “Company”) submitted a Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”), seeking approval of its tri-specific nanobody sonelokimab for the treatment of moderate-to-severe hidradenitis suppurativa in adults and pediatric …Other event · Form 8-K
- Aug 10, 2026MoonLake Announces Positive Topline Results.Earnings release · press release
- Jul 15, 2026On July 10, 2026, the underwriters of the previously announced public offering of Class A ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), of MoonLake Immunotherapeutics (the “Company”) and, in lieu of Ordinary Shares to certain investors that so choose, pre-funded warrants to purchase Ordinary …Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.